Q&As on Annual Reports

Sort By:

Company Name:

Market:

Array
(
    [0] => WP_Post Object
        (
            [ID] => 9552
            [post_author] => 1
            [post_date] => 2021-10-01 11:30:09
            [post_date_gmt] => 2021-10-01 03:30:09
            [post_content] => 
            [post_title] => iX Biopharma Ltd
            [post_excerpt] => 
            [post_status] => publish
            [comment_status] => closed
            [ping_status] => closed
            [post_password] => 
            [post_name] => ix-biopharma-ltd-4
            [to_ping] => 
            [pinged] => 
            [post_modified] => 2021-10-06 17:26:54
            [post_modified_gmt] => 2021-10-06 09:26:54
            [post_content_filtered] => 
            [post_parent] => 0
            [guid] => https://sias.org.sg/?post_type=annual_reports&p=9552
            [menu_order] => 0
            [post_type] => annual_reports
            [post_mime_type] => 
            [comment_count] => 0
            [filter] => raw
        )

    [1] => WP_Post Object
        (
            [ID] => 5477
            [post_author] => 26
            [post_date] => 2018-10-03 17:09:56
            [post_date_gmt] => 2018-10-03 09:09:56
            [post_content] => 
            [post_title] => iX Biopharma Ltd
            [post_excerpt] => 
            [post_status] => publish
            [comment_status] => closed
            [ping_status] => closed
            [post_password] => 
            [post_name] => ix-biopharma-ltd-3
            [to_ping] => 
            [pinged] => 
            [post_modified] => 2019-05-28 12:32:12
            [post_modified_gmt] => 2019-05-28 04:32:12
            [post_content_filtered] => 
            [post_parent] => 0
            [guid] => https://sias.org.sg/?post_type=annual_reports&p=5477
            [menu_order] => 0
            [post_type] => annual_reports
            [post_mime_type] => 
            [comment_count] => 0
            [filter] => raw
        )

    [2] => WP_Post Object
        (
            [ID] => 4361
            [post_author] => 1
            [post_date] => 2018-07-26 19:42:19
            [post_date_gmt] => 2018-07-26 11:42:19
            [post_content] => 
            [post_title] => iX Biopharma Ltd
            [post_excerpt] => 
            [post_status] => publish
            [comment_status] => open
            [ping_status] => open
            [post_password] => 
            [post_name] => ix-biopharma-ltd-2
            [to_ping] => 
            [pinged] => 
            [post_modified] => 2018-08-14 16:22:19
            [post_modified_gmt] => 2018-08-14 08:22:19
            [post_content_filtered] => 
            [post_parent] => 0
            [guid] => http://sias2017.php-dp.com/annual_reports/ix-biopharma-ltd-2/
            [menu_order] => 0
            [post_type] => annual_reports
            [post_mime_type] => 
            [comment_count] => 0
            [filter] => raw
        )

    [3] => WP_Post Object
        (
            [ID] => 4129
            [post_author] => 1
            [post_date] => 2018-07-26 19:40:39
            [post_date_gmt] => 2018-07-26 11:40:39
            [post_content] => 
            [post_title] => iX Biopharma Ltd
            [post_excerpt] => 
            [post_status] => publish
            [comment_status] => open
            [ping_status] => open
            [post_password] => 
            [post_name] => ix-biopharma-ltd
            [to_ping] => 
            [pinged] => 
            [post_modified] => 2018-08-14 16:22:14
            [post_modified_gmt] => 2018-08-14 08:22:14
            [post_content_filtered] => 
            [post_parent] => 0
            [guid] => http://sias2017.php-dp.com/annual_reports/ix-biopharma-ltd/
            [menu_order] => 0
            [post_type] => annual_reports
            [post_mime_type] => 
            [comment_count] => 0
            [filter] => raw
        )

)
Array
(
    [company] => iX Biopharma Ltd
    [cid] => 9552,5477,4361,4129
)
Array
(
    [post_type] => annual_reports
    [showposts] => -1
    [meta_key] => agm_date
    [orderby] => Array
        (
            [meta_value] => DESC
            [title] => ASC
        )

    [order] => DESC
    [paged] => 1
    [post_title_like] => iX Biopharma Ltd
    [meta_query] => Array
        (
            [key] => mark_as_upcoming_qa
            [value] => 
            [compare] => =
        )

)

Array
(
    [0] => WP_Post Object
        (
            [ID] => 9552
            [post_author] => 1
            [post_date] => 2021-10-01 11:30:09
            [post_date_gmt] => 2021-10-01 03:30:09
            [post_content] => 
            [post_title] => iX Biopharma Ltd
            [post_excerpt] => 
            [post_status] => publish
            [comment_status] => closed
            [ping_status] => closed
            [post_password] => 
            [post_name] => ix-biopharma-ltd-4
            [to_ping] => 
            [pinged] => 
            [post_modified] => 2021-10-06 17:26:54
            [post_modified_gmt] => 2021-10-06 09:26:54
            [post_content_filtered] => 
            [post_parent] => 0
            [guid] => https://sias.org.sg/?post_type=annual_reports&p=9552
            [menu_order] => 0
            [post_type] => annual_reports
            [post_mime_type] => 
            [comment_count] => 0
            [filter] => raw
        )

    [1] => WP_Post Object
        (
            [ID] => 5477
            [post_author] => 26
            [post_date] => 2018-10-03 17:09:56
            [post_date_gmt] => 2018-10-03 09:09:56
            [post_content] => 
            [post_title] => iX Biopharma Ltd
            [post_excerpt] => 
            [post_status] => publish
            [comment_status] => closed
            [ping_status] => closed
            [post_password] => 
            [post_name] => ix-biopharma-ltd-3
            [to_ping] => 
            [pinged] => 
            [post_modified] => 2019-05-28 12:32:12
            [post_modified_gmt] => 2019-05-28 04:32:12
            [post_content_filtered] => 
            [post_parent] => 0
            [guid] => https://sias.org.sg/?post_type=annual_reports&p=5477
            [menu_order] => 0
            [post_type] => annual_reports
            [post_mime_type] => 
            [comment_count] => 0
            [filter] => raw
        )

    [2] => WP_Post Object
        (
            [ID] => 4361
            [post_author] => 1
            [post_date] => 2018-07-26 19:42:19
            [post_date_gmt] => 2018-07-26 11:42:19
            [post_content] => 
            [post_title] => iX Biopharma Ltd
            [post_excerpt] => 
            [post_status] => publish
            [comment_status] => open
            [ping_status] => open
            [post_password] => 
            [post_name] => ix-biopharma-ltd-2
            [to_ping] => 
            [pinged] => 
            [post_modified] => 2018-08-14 16:22:19
            [post_modified_gmt] => 2018-08-14 08:22:19
            [post_content_filtered] => 
            [post_parent] => 0
            [guid] => http://sias2017.php-dp.com/annual_reports/ix-biopharma-ltd-2/
            [menu_order] => 0
            [post_type] => annual_reports
            [post_mime_type] => 
            [comment_count] => 0
            [filter] => raw
        )

    [3] => WP_Post Object
        (
            [ID] => 4129
            [post_author] => 1
            [post_date] => 2018-07-26 19:40:39
            [post_date_gmt] => 2018-07-26 11:40:39
            [post_content] => 
            [post_title] => iX Biopharma Ltd
            [post_excerpt] => 
            [post_status] => publish
            [comment_status] => open
            [ping_status] => open
            [post_password] => 
            [post_name] => ix-biopharma-ltd
            [to_ping] => 
            [pinged] => 
            [post_modified] => 2018-08-14 16:22:14
            [post_modified_gmt] => 2018-08-14 08:22:14
            [post_content_filtered] => 
            [post_parent] => 0
            [guid] => http://sias2017.php-dp.com/annual_reports/ix-biopharma-ltd/
            [menu_order] => 0
            [post_type] => annual_reports
            [post_mime_type] => 
            [comment_count] => 0
            [filter] => raw
        )

)
Array
(
    [company] => iX Biopharma Ltd
    [cid] => 9552,5477,4361,4129
)
Array
(
    [post_type] => annual_reports
    [showposts] => 12
    [meta_key] => agm_date
    [orderby] => Array
        (
            [meta_value] => DESC
            [title] => ASC
        )

    [order] => DESC
    [paged] => 1
    [post_title_like] => iX Biopharma Ltd
    [meta_query] => Array
        (
            [key] => mark_as_upcoming_qa
            [value] => 
            [compare] => =
        )

)

AGM Date	Company	Market	Annual Report	SIAS Questions	Company Response
AGM Date: 15/10/2021	15/10/2021	Company: iX Biopharma Ltd	iX Biopharma Ltd	Market: Catalist	Catalist	Annual Report: Download	Download	SIAS Questions	What are the critical milestones to obtain the “marketing authorisation” for Wafesil... Read More
AGM Date: 19/10/2018	19/10/2018	Company: iX Biopharma Ltd	iX Biopharma Ltd	Market: Catalist	Catalist	Annual Report: Download	Download	SIAS Questions	1. Can management help shareholders understand the R&D budget set aside... Read More
AGM Date: 24/10/2017	24/10/2017	Company: iX Biopharma Ltd	iX Biopharma Ltd	Market: Catalist	Catalist	Annual Report: Download	Download	SIAS Questions	1. The group report a revenue increase of 10% to $6.4 million in 2017... 2. The group has developed a new pipeline of nutraceutical products and... 3. As disclosed in the Corporate Governance Report (page 29), a sum of $130,000... Read More	Company Response	1. Revenue of Chemical Analysis increased 7% in FY2017 over FY2016. There... 2. We have identified 5 major regions in which we are exploring launching... 3. During FY2017, Centrum Capital had been engaged to provide... Read More
AGM Date: 25/10/2016	25/10/2016	Company: iX Biopharma Ltd	iX Biopharma Ltd	Market: Catalist	Catalist	Annual Report: Download	Download	SIAS Questions	1. New drug application is extremely costly and time consuming and shareholders may not be... 2. For the benefit of the current shareholders, the group must manage its expenses and cash... 3. In the Remuneration section in the Corporate Governance report (page 19), the... Read More	Company Response	1. Product: Wafermine™ Sublingual ketamine; PheoniX™ Sublingual... 2. Excluding share - based compensation, clinical t rials and... 3. RC commissioned Carrots Consulting to review the... Read More

Upcoming Q&A

Securities Investors Association (Singapore)
7 Maxwell Road #05-03
MND Building Annexe B
Singapore 069111

Securities Investors Association (Singapore) @2023 All rights reserved.